Companies › Amydis
1 active drug program in 2 registered trials: 2 Phase 2; Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AMDX-2011P diagnostic imaging agent for cerebral amyloid angiopathy | – | Phase 2 | Cerebral Amyloid Angiopathy; Alzheimer Disease | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05709314 | AMDX-2011P | Phase 2 | Cerebral Amyloid Angiopathy | Neurology | Dec 2026 |
| NCT06514001 | AMDX-2011P | Phase 2 | Alzheimer Disease | Neurology | Jul 2027 |
No annotated target.
–
Dasher Neuroscience ThromBio Appello Pharmaceuticals PhenoNet Glycomine
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.